INSIGHTS ON DRUG DISCOVERY

Preclinical Evaluation Of Vaccines And Antivirals In RSV Challenge Rodent Models
Here, we present multiple case studies utilizing clinically relevant mouse and rat models to evaluate key characteristics of potential RSV therapeutics.
Preclinical Evaluation Of New Antifibrotics In NASH-Induced Fibrosis Models
Accelerate the development of antifibrotic therapies through our clinically relevant models, deep scientific expertise, and proven preclinical capabilities in this area of unmet medical need.
Preclinical Evaluation Of Antifibrotics In COVID-Induced Fibrosis Model
Advancing the development of effective antifibrotic therapies requires urgent investment in clinically relevant, IND-enabling preclinical models to address the growing burden of fibrotic diseases.
Preclinical Evaluation Of Vaccines And Antivirals In RSV Challenge SCID Mouse Models
Advance your RSV therapeutic pipeline with trusted, IND-enabling preclinical services that deliver clinically relevant data through optimized study designs and validated rodent models.

Preclinical Evaluation Of RSV Vaccines And Antivirals In BALB/c Mice
6/10/2025

Accelerate your RSV therapeutic development with clinically relevant preclinical models and expert IND-enabling services that deliver the data needed to advance confidently toward clinical trials.
You Need 'Brutal Honesty' When Outsourcing
5/29/2025

Our Outsourced Pharma Live speakers were adamant: You need a clear and honest assessment of what both the sponsor and CDMO need and bring to the relationship.
A Brief Intro To CMC Compliance Through CDMO Collaborations
5/29/2025

Chief Editor Louis Garguilo provides a brief introduction and background to our Outsourced Pharma Live Event: CMC Compliance Through CDMO Collaborations.
The 3 Models Of Outsourcing
5/29/2025

Jumai Abioye, Ph.D., Founder and CEO, Pan Access Innovations, offers her three models of outsourcing and working with CDMOs, for biotechs of all shapes and sizes.
Broad Biodistribution And Expression Of Allele-Selective LETI-101
5/28/2025

Discover how LETI-101, a novel precision-based CRISPR treatment, can leverage targeted delivery and broad brain distribution to transform Huntington's disease treatment.

DRUG DISCOVERY SOLUTIONS

Analytical Labs Particle Analysis

Particulate in a drug product represents a huge risk not only to patient safety – but also to a drug company’s reputation and bottom line. As concern about particulate rises, partnering with a particle analysis team enables customers to gain an intimate understanding of particle sources related to packaging and delivery systems.
Aragen's Preclinical Oncology Capabilities

We provide specialized in vivo pharmacology services, offering customized solutions to support the development of immune-oncology therapies from discovery to commercialization.
End-To-End Services In Contract Manufacturing

Discover how flexible, high-quality manufacturing solutions support biopharma innovation and help bring effective therapies to patients around the world.
Surfactant Analysis Services

Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.
Bioengineering Solutions Using A Fully Integrated Ecosystem

Find solutions to meet your gene, protein, antibody, or cell line needs using two gene synthesis platforms that enable the design of constructs optimized for maximal expression/yield in your system.